Xeris Biopharma (NASDAQ:XERS) Stock: Insider Kevin Mcculloch Sells 25,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 25,000 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the sale, the insider owned 1,559,208 shares in the company, valued at $19,474,507.92. This trade represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, November 2nd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $10.23, for a total transaction of $153,450.00.
• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total transaction of $127,350.00.

Xeris Biopharma Price Performance

Shares of XERS opened at $15.20 on Friday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $15.21. The firm’s 50 day moving average price is $9.62 and its 200 day moving average price is $7.62. The company has a market cap of $2.77 billion, a P/E ratio of -303.94 and a beta of 0.61. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 429.43%. The company had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in XERS. BlackRock Inc. purchased a new position in Xeris Biopharma in the second quarter worth approximately $115,042,000. Wellington Management Group LLP grew its holdings in Xeris Biopharma by 8.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock worth $18,732,000 after acquiring an additional 193,749 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Xeris Biopharma in the 2nd quarter valued at approximately $15,941,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Xeris Biopharma in the 2nd quarter valued at approximately $14,316,000. Finally, Algert Global LLC increased its position in shares of Xeris Biopharma by 50.6% in the 2nd quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock valued at $13,804,000 after purchasing an additional 585,984 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on XERS. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. Piper Sandler reissued a “neutral” rating and set a $12.00 target price (up from $8.00) on shares of Xeris Biopharma in a research note on Friday. Leerink Partners upped their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Finally, Oppenheimer restated an “outperform” rating and set a $21.00 price target (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.20.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.